Hubei Guangji Pharmaceutical Technology Co., Ltd.

Primary objective: To evaluate the pharmacokinetic characteristics of ruxolitinib phosphate tablets (test preparation, specification: 5 mg; produced by Chongqing Boteng Pharmaceutical Co., Ltd.) produced by Hubei Guangji Pharmaceutical Technology Co., Ltd. and ruxolitinib phosphate tablets (reference preparation, specification: 5 mg, trade name: Jakavi) produced by Novartis Pharma Stein AG, Switzerland under the conditions of single fasting/fed administration (5 mg) in healthy Chinese subjects, and to evaluate the bioequivalence of the test preparation and the reference preparation. Secondary objective: To evaluate the safety of single administration of 5 mg test preparation ruxolitinib phosphate tablets and 5 mg reference preparation ruxolitinib phosphate tablets (Jakavi) under fasting and fed conditions in healthy Chinese subjects.